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Abstract 
 
Background LDL uptake by monocyte-derived macrophages (MDMs) is a crucial step in foam 
cell formation and early atherosclerotic lesion. Increasing evidence supports that activation of 
PKCβ  is involved in many mechanisms promoting atherosclerosis. Thus, we investigate whether 
inhibition of PKCβ prevents foam cell formation. Methods and Results The differentiation of 
human primary monocytes or monocytic THP-1 cell line into MDMs was induced by phorbol 12-
myristate 13-acetate (PMA, 0.1 mmol/L), a potent activator of PKC. Incubation of MDMs with 
DiI-modified LDL (acLDL and oxLDL, 10 µg/mL) led to lipoprotein uptake. Interestingly 
enough, the non-selective inhibitor of PKCβ1 and PKCβ2, LY379196 (5x10-7-10-5 mol/L) blunted 
LDL uptake in MDMs as shown by flow-cytometry. Specific siRNA-mediated knockdown of 
PKCβ exerted similar effect. Furthermore, PMA alone and in the presence of modified LDL 
induced scavenger receptor A (SR-A) mRNA and protein expression which was abolished by 
LY379196. CGP53353, a selective inhibitor of PKCβ2 , did not affect LDL uptake nor did it 
prevent SR-A upregulation. Incubation of MDMs with PMA/LDL increased PKCβ1 
phosphorylation at the Thr-642 residue, which was blunted by LY379196. However the 
expression of CD68, a marker of activated macrophages, was not affected by LY379196. 
Moreover, LY379196 did not affect LPS-induced CD14 degradation, TNFα release nor  
superoxide anion production, ruling out any effect of PKCβ inhibition on innate immunity. 
Conclusions Non-specific inhibition of PKCβ prevents LDL uptake in macrophages. These 
findings suggest that PKCβ inhibitors may represent a novel class of antiatherosclerotic drugs.    
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Protein kinase C (PKC) comprises several structurally related serine/threonine kinases 
classified in 3 groups. The “conventional” or “classical” PKCs include PKC α, β1, β2, γ. These 
isoforms can be activated by Ca2+ and/or by diacylgycerol (DAG) as well as phorbol esters. The 
“novel” PKC δ, ε, θ are also activated by DAG and phorbol esters but are Ca2+ independent. The 
“atypical” PKCs, which include PKCζ and PKCι, are unresponsive to Ca2+/DAG and phorbol 
esters.1 Particularly interesting is the modulation of PKC activity by phosphorylation of serine 
and threonine amino acid residues within its catalytic and regulatory domains.2 Both 
conventional and novel PKC isoforms can traslocate to the membranous compartment of the cell 
to elicit biological actions in the presence of DAG, of which the de novo synthesis is increased by 
hyperglycemia.3 Indeed, the activation of PKC pathway, especially the PKCβ isoform, has been 
shown extensively to cause diabetic vascular dysfunction.4-7  As non-selective PKC inhibition is 
associated with lethal side effects, isoform-specific inhibitors have been developed. The 
macrocyclic bis (indolyl) maleimides, like ruboxistaurin (LY333531), LY379196, LY317615 and 
LY290181 are competitive inhibitors of ATP binding site within the PKC molecule.8,9 The 
advantage of macrocyclic bis (indolyl) maleimides is their high selectivity for PKCβ in 
comparison to other isoforms of PKC.10 Treatment of diabetic patients for 3 months with 
PKC412, a multitarget kinase inhibitor, which also acts as a nonselective PKC inhibitor, resulted 
in significant gastrointestinal side effects such as nausea, vomiting and diarrhea as well as liver 
toxicity.11 On the contrary, a multicenter, randomized clinical trial with the selective PKCβ 
inhibitor ruboxistaurin in patients with diabetic retinopathy revealed that the oral administration 
of this drug was well tolerated and did not cause any adverse events in patients with diabetes at 
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doses up to 16 mg twice daily for 28 days.12 Furthermore in patients with type 1 and 2 diabetes 
and minimal retinopathy, retinal blood flow was increased by the PKCβ inhibitor in a dose-
dependent fashion.13  Treatment for over 1 year with ruboxistaurin has shown beneficial effects in 
delaying the progression of diabetic nephropathy.14 These studies provided the first 
demonstration that a PKCβ isoform-selective inhibitor can be used for long term clinical 
treatment of diabetic microangiopathy with minimal side effects.15 However, increasing evidence 
suggests that activation of PKCβ  is involved in many mechanisms promoting atherosclerosis.16 
Interestingly, phorbol 12-myristate 13-acetate (PMA), a structural analogue of DAG - natural 
activator of PKC - can trigger transformation of monocytes to macrophages.17 The accelerated 
atherosclerosis18 and chronic activation of PKCβ in vascular tissues of diabetic patients, 
including the retina, heart, aorta and circulating monocytes4,19,20 prompted us to hypothesize that 
PKCβ among all PKC isoforms could be involved in foam cell formation.   
The present study was designed to investigate whether selective pharmacological inhibition of 
PKCβ results in prevention of modified LDL uptake and, hence, foam cell formation. Our 
findings unmask an antiatherosclerotic effect of PKCβ inhibitors extending their application far 
beyond diabetic vascular complications. 
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Methods 
 
Cell  culture 
Peripheral blood mononuclear cells were isolated from healthy control subjects by density 
centrifugation in BD vacutainer cell preparation tubes with sodium heparin (Becton Dickinson) 
and further purified by MACS sorting with anti –human CD14 antibody (Miltenyi Biotec, 
Germany) conjugated with magnetic beads. After density centrifugation, highly purified 
monocytes were recovered. Human monocyte purity was assessed by flow cytometry 
(FACSCanto (Becton Dickinson) using FITC-conjugated anti-human CD14 antibody (Miltenyi 
Biotec). The human monocytic THP-1 cell line was obtained from the American Type Culture 
Collection (Rockville, MD, USA). Monocytes were cultured in RPMI 1640 medium containing 
25 mmol/L Hepes buffer [supplemented with 10% fetal calf serum (FCS), 1% L-glutamine 200 
mmol/L, 100 U/mL penicillin, and 100µg/mL streptomycin] in humidified air, 5%CO2 at 37°C. 
Freshly isolated human monocytes and THP-1 monocytes were differentiated into MDMs in vitro 
by treatment with 0.1 µmol/L PMA (Calbiochem, Darmstadt, Germany) for overnight in 
starvation medium 0.5% FCS RPMI 1640. During starvation the cells were exposed to 
LY379196 (10-6 mol/L), a non-selective inhibitor of both PKCβ isoforms, CGP53353 (10-6 
mol/L), a PKCβ2 selective inhibitor and then incubated for further 24 hours in the presence of 10 
µg/mL DiI-labeled acetylated low density lipoprotein (DiI-acLDL) and DiI-labeled oxidized low 
density lipoprotein (DiI-oxLDL) (Intracel, Frederick, MD, USA). Human MDMs were also 
pretreated with myristoylated cell-permeable myr-ψPKC peptide (10-4 mol/L), based on the 
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pseudosubstrate motif of PKC β which keep the enzyme in an inactive state by interacting with 
the substrate binding site of PKC β catalytic domain.21 In another set of experiments MDMs were 
pretreated with the two PKCβ inhibitors or myr-ψPKC and stimulated for 24 hours with 100 
ng/mL, lipopolysaccharide (LPS, Sigma, Buchs, Switzerland). Afterwards TNFα levels were 
measured in cell supernatant by ELISA (R&D Systems, Minneapolis, MN, USA). To exclude 
cytotoxicity, a colometric assay for detection of lactate dehydrogenase in cell supernatant was 
performed according to the manufacturer’s recommendations (Roche, Basel, Switzerland). 
 
siRNA transfection 
Transfections were performed using INTERFERin TM (Polyplus Transfection, Switzerland) 
according to the manufacturer’s instructions in Human MDMs (THP-1 cell line). Commercially 
available Human PKCβ, GAPDH (Santa Cruz, Germany) specific siRNAs were used for 
transfecting. The MDMs were transfected after 24hrs of seeding. 8 µl of INTERFERin 
transfection reagent (Polyplus) was added to 100 µl of OptiMEM serum-free medium containing 
80 nM of each siRNA oligo, incubated for 10 minutes, and added to the 3 cm plate containing 2 
ml of medium. GAPDH siRNA was used as a negative control. The control siRNA A – FITC 
labelled (Santa Cruz, Germany) was used as a marker for transfection efficiency. Gene silencing 
was measured after 48h by western blotting. The transfected cells were incubated for further 24 
hours in the presence of 10 µg/mL DiI-acLDL (Intracel, Frederick, MD, USA) and acLDL uptake 
was measured by Flow cytometry. Another set of transfected MDMs were used to perform 
western blotting. 
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Real Time PCR 
Total RNA was extracted from MDMs (THP-1 cell line) using Trizol Reagent (Invitrogen, Basel, 
Switzerland) according to the manufacturer’s recommendations. Conversion of the total cellular 
RNA to cDNA was carried out with Moloney murine leukemia virus reverse transcriptase and 
random hexamers (Amersham Bioscience, Otelfingen, Switzerland) in a final volume of 35 µL, 
using 4 µg of cDNA according to manufacturer recommendations. Real time PCR was performed 
in a MX3000P PCR cycler (Stratagene, La Jolla, CA).  All PCR experiments were performed in 
triplicates using the SYBR Green JumpStart kit provided by Sigma. Each reaction (25 µL) 
contained 2 µL cDNA, 1 pmol of each primer, 0.25 µL of internal reference dye and 12.5 µL of 
JumpStart Taq ReadyMix (containing buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase 
and JumpStart Taq antibody). The following primers were used. For SR-A: sense primer: 5’-
CCAGGGACATGGGAATGCAA–3’, antisense primer: 5’–CCAGTGGGACCTCGATCTCC–
3’. For human L28: sense primer: 5’–GCATCTGCAATGGATGGT-3’, antisense primer: 5’–
TGTTCTTGCGGATCATGTGT-3’. The amplification program consisted of 1 cycle at 95˚C for 
10 min, followed by 40 cycles with a denaturing phase at 95˚ C for 30 s, an annealing phase of 1 
min at 60˚ C and an elongation phase at 72˚C for 1 min. A melting curve analysis was performed 
after amplification to verify the accuracy of the amplicon. For verification of the correct 
amplification, PCR products were analyzed on an ethidium bromide stained 1% agarose gel. In 
each real-time PCR run for F3 and L28 a calibration curve was included, that was generated from 
serial dilutions (2x107, 2x106,  2x105, 2x104, 2x103, 2x103, copies/reaction for SR-A, and 2x107, 
2x106,  2x105, 2x104, 2x103, 2x103 copies/reaction for L28) of purified amplicons for SR-A and 
L28. 
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Western blotting 
Human MDMs, THP-1 cell line and freshly isolated blood Monocytes (where indicated), were 
washed twice with PBS and harvested in the extraction buffer (120 mmol/L sodium chloride, 50 
mmol/L Tris, 20 mmol/L sodium fluoride, 1 mmol/L benzamidine, 1 mmol/L DTT, 1 mmol/L 
EDTA, 6 mmol/L EGTA, 15 mmol/L sodium pyrophosphate, 0.8 µg/mL leupeptin, 30 mmol/L p-
nitrophenyl phosphate, 0.1 mmol/L PMSF, and 1% NP-40) for immunoblotting. All cell debris 
were removed by centrifugation (12 000 g) for 10 minutes at 4°C. The protein extracts (20 µg) 
were treated with 5x Laemmli’s SDS-PAGE sample buffer (0.35 mol/L Tris-Cl, pH 6.8, 15% 
SDS, 56.5% glycerol, 0.0075% bromophenol blue), followed by heating at 99°C for 5 minutes, 
and then applied to 10% SDS-polyacrylamide gel for electrophoresis. The proteins were then 
transferred onto Immobilon-P filter papers (Millipore AG, Bedford, MA) with a semidry transfer 
unit (Hoefer Scientific, San Francisco, CA). The membranes were then blocked by use of 5% 
skim milk in TBS-Tween buffer (0.1% Tween 20; pH 7.5) for 1 hour and incubated overnight 
with the anti-human SR-A (1:500, TransGenic, Kobe, Japan), anti-human LOX-1 (1:4000, R&D 
Systems, Germany), anti-phospho-Thr-642 PKCß1 (1:1000, Biosource, Nivelles, Belgium), anti 
PKCβ-1 (1:1000, Santa Cruz, Germany), anti-CD14 (1:1000, Dako Cytomation, Baar, 
Switzerland) antibody in 0.5% BSA PBS. Antigen detection was performed with an enhanced 
chemiluminescence detection system (Amersham Biosciences, Otelfingen, Switzerland).  
 
LDL uptake measurement by flow cytometry 
After incubation with DiI-acLDL (10µg/mL) and DiI-oxLDL (10µg/mL) human MDMs both 
freshly isolated and THP-1 cell line were subjected to flow cytometry in order to measure the 
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amount of internalized LDL. Adherent and non adherent cells were harvested by gentle scraping. 
Cells were then washed twice with PBS and resuspended in 0.2% BSA in PBS. Samples were 
analyzed using flow cytometer Facscanto II (BD, Heidelberg, Germany) and software “Flowjo”.  
 
Measurements of superoxide anion production  
Superoxide production in MDMs, both freshly isolated and THP-1 cell line, treated with 
LY379196 (10-6 mol/L) and silencing of PKC β was determined by electron spin resonance 
(ESR) spectroscopy analysis using the spin trap CM-H (1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine; Noxygen; Elzach; Germany) as described previously.22  In brief, MDMs 
were centrifuged (380 g; 5 min) and resuspended in Krebs-HEPES buffer (pH 7.35) containing 
diethyldithiocarbamate (DETC; 5μM) and deferoxamine (25μM).  ESR spectra were recorded 
using a Bruker e-scan ESR spectrometer (Bruker Corporation) after the addition of the spin trap 
CM-H (200μM) under stable temperature conditions (37° C; temperature control system).  The 
ESR instrumental settings were as follows: center field, 3495 G; field sweep width, 10.000 G; 
microwave frequency, 9.75 GHz; microwave power, 19.91 mW; magnetic field modulation 
frequency, 86.00 kHz; modulation amplitude, 2.60 G; conversion time, 10.24 msec; detector time 
constant, 328 msec; number of x-scans, 10.   
 
Confocal Fluorescent Microscopy 
Human MDMs were washed once with PBS, fixed in 4% paraformaldehyde for 10 min, washed 
again with PBS, blocked with 0.1 mol/L glycine for 5 min, permeabilized with 0.2% Triton 100 
for 7 min and incubated overnight with anti-human SR-A (TransGenic, Kobe, Japan), anti-PKCß1 
(Biosource, Nivelles, Belgium), anti-PKCß2 (Biosource, Nivelles, Belgium) or anti-CD68 (Dako 
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Cytomation, Baar, Switzerland) antibodies in 0.2% BSA. Afterwards the cells were washed three 
times with PBS and were incubated with secondary alexa fluor488-labeled antibody (Molecular 
Probes, Eugene, OR) in 0.2% BSA for 1 hour. Cells were counterstained with 4’, 6 diamidino-2-
phenylindol (DAPI, Vector Laboratories, Burlingame, CA) and analyzed using Leica confocal 
laser microscope. 
 
Drugs 
LY379196 was provided by Eli Lilly (Indianapolis, IA, USA). CGP53353 was kindly provided 
by Dr. Doriano Fabbro (Novartis Pharma AG, Basel, Switzerland). Calphostin C, PMA and myr-
ψPKC were purchased from Calbiochem (Darmstadt, Germany). LPS was obtained from Sigma 
(Buchs, Switzerland). 
 
Statistical Analysis 
Results are expressed as mean±SEM and n indicates number of experiments. Statistical 
evaluation of the data was performed with Student’s t test for simple comparison between 2 
values when appropriate. For multiple comparisons results were analyzed by ANOVA followed 
by Fisher’s test. A value of p<0.05 was considered statistically significant.  
The authors had full access to and take full responsibility for the integrity of the data. All authors 
have read and agree to the manuscript as written. 
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Results 
 
Role of PKCβ in mediating human MDM foam cell formation  
The differentation of human primary monocytes and monocytic THP-1 cell line into 
macrophages (MDMs) was induced by PMA (0.1µmol/L). Incubation of human MDMs with DiI-
acLDL (10 µg/mL) led to binding of acLDL to the plasma membrane and accumulation of 
lipoproteins into the cytoplasm as assessed by fluorescence microscopy (Figure 1A). The non-
selective inhibitor of both PKCβ isoforms LY379196 (10-6mol/L) abolished acLDL uptake in 
MDMs as shown in Figure 1B. To identify the isoform of PKCβ involved, human MDMs were 
exposed to selective antibodies against PKCβ1 and PKCβ2.  PKCβ isoforms were localized in the 
nucleus as well as in cytoplasm of MDMs, showing an activated state of the enzyme. PKCβ1 
isoform was homogeneously distributed within the cytoplasm and plasma membrane (Figure 1C), 
while PKCβ2 was present in the perinuclear patch and plasma membrane (Figure 1D). 
Accordingly, LY379196 showed a dose-dependent decrease of both acLDL and oxLDL uptake in 
MDMs by flow-cytometry (Figure 2A and B). In contrast, selective inhibitor of PKCβ2 
CGP53353 did not exert any significant effect (data not shown).  
 
Effect of PKCβ inhibition on SR-A expression  
To delineate the molecular mechanism by which LY379196 blunted modified LDL uptake 
MDMs gene and protein expression of scavenger receptor A (SR-A) were determined. Quiescent 
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cells did not express SR-A mRNA, stimulation with PMA (0.1µmol/L) increased SR-A 
expression (Figure 3). A more pronounced upregulation of SR-A expression was achieved by 
addition of acLDL (10 µg/mL) to the medium. SR-A mRNA expression was abolished by 
treatment with LY379196 (10-6 mol/L), whereas CGP53353 (10-6 mol/L) did not exert any 
inhibitory effect on PMA/acLDL-induced SR-A expression in human MDMs (Figure 3). In 
agreement with these results, SR-A protein expression was increased after exposure to acLDL as 
well as oxLDL (Figure 4A and B). Treatment with LY379196, but not with CGP53353, totally 
abrogated PMA/acLDL-induced macrophage SR-A expression (Figure 4A). When MDMs were 
exposed to oxLDL in the presence of LY379196 (10-6mol/L) showed similar results (Figure 4B). 
A myristoylated cell-permeable myr-ψPKC inhibitory peptide was used to confirm the 
modulatory role of PKCβ on SR-A expression. As LY379196, the inhibitory peptide myr-ψPKC 
(10-4mol/L) significantly blunted SR-A protein expression in human MDMs (Figure 4C).  
In contrast to SR-A, LOX-1 protein expression did not change after exposure of MDMs with 
modified LDL. Furthermore, LY379196 (10-6mol/L) did not exert any significant effect on LOX-
1 expression (Figure 4D). 
 
Effect of silencing PKCβ on LDL uptake and SR-A expression 
The transfection of PKCβ siRNA into MDMs resulted in reduced expression of the protein, 
whereas the GAPDH and Mock controls did not exert any significant effect (Figure 5A). We 
examined with flow cytometry the DI-acLDL uptake by the transfected cells. PKCβ silencing 
reduced the uptake and blunted SR-A protein expression, reproducing the same effect as that of 
the pharmacological inhibitor LY379196 (Figure 5B and C). 
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Role of Thr-642 phosphorylation in PKCβ1-mediated SR-A Expression 
Western blotting with an antibody against phosphorylated PKCβ1 at specific amino residue 
revealed that incubation of the cells with PMA/acLDL increased Thr-642 phosphorylation within 
the catalytic domain of this molecule (Figure 6). The inhibitor of both PKCβ isoforms, LY379196 
(10-6 mol/L) as well as inhibitory peptide myr-ψPKC (10-4mol/L) blunted PMA/acLDL-induced 
Thr-642 phosphorylation (Figure 6), suggesting that phopsphorylation of PKCβ1 at Thr-642 may 
thus represent a selective regulatory mechanism for SR-A upregulation. Accordingly, the 
selective PKCβ2 inhibitor CGP53353 (10-6 mol/L) did not affect Thr-642 phosphorylation (Figure 
6). 
 
Effect of PKCβ inhibition on Macrophage Activation and Functioning 
As shown by confocal microscopy, high levels of SR-A expression in MDMs stimulated with 
acLDL were blunted in the presence of LY379196 (Figure 7A and B). However, LY379196 did 
not exert any effect on the expression of CD68, a marker of macrophage activation, (Figure 7 C 
and D). In addition, human MDMs were exposed to LPS (100 ng/mL) to rule out an effect of 
PKCβ inhibition on macrophage functioning in innate immunity. LPS elicited degradation of 
CD14 and secretion of TNFα, crucial steps in the activation of innate immunity (Figure 8A and 
B). Interestingly enough, increasing concentrations of LY379196 did not inhibit neither LPS-
induced CD14 degradation (Figure 8A) nor TNFα release (Figure 8B). Treatment with 
LY379196 did not elicit any release of LDH (data not shown), ruling out that its effects on 
human MDMs were due to cellular toxicity. In agreement with this finding, no apoptotic nuclei 
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by DAPI staining were observed (Figure 7).  Furthermore, effect of LY379196 (10-6 mol/L) on 
the ability of macrophages to produce superoxide anion (O2-) was measured. No significant 
changes in O2- production were observed (Figure 8C). Also silencing of PKCβ did not affect O2- 
production (data not shown). 
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Discussion 
 
Accumulation of cholesterol-loaded foam cells in the arterial intima is a hallmark and key event 
of early atherogenesis.23 Circulating monocytes adhere to activated endothelial cells and 
transmigrate into the subintima to become tissue macrophages. Upon exposure to modified 
lipoproteins such as the oxidized and acetylated forms of low-density lipoproteins (oxLDL and 
acLDL), these macrophages become foam cells.24 Two receptors appear to be essential in foam 
cell formation and receptor-mediated binding/ uptake of modified lipoproteins: CD36 and SR-
A.25 Despite increasing evidence supports that PKC is involved in many mechanisms promoting 
atherosclerosis,16 only few studies have examined the role of PKC signaling in foam cell 
formation.20, 26  
In this study we demonstrated that inhibition of PKCβ prevents uptake of modified LDL by 
reducing human MDMs SR-A expression. Several lines of evidence support this conclusion. 
First, FACS analysis revealed that the non-selective inhibitor of PKCβ isoforms blunted modified 
LDL uptake of human MDMs. Second, silencing of PKCβ by siRNA transfection also reduced 
LDL uptake. Third, we observed a selective Thr-642 phosphorylation within the catalytic domain 
of PKCβ1 as well as increase of SR-A mRNA and protein expression in human MDMs exposed 
to modified LDL. Fourth, both LY379196 and inhibitory peptide myr-ψPKC blunted 
phosphorylation of Thr-642 and upregulation of SR-A. By contrast CGP53353, the selective 
inhibitor of PKCβ2.7 did not exert any significant effect.  
Expression and function of macrophage SR-A plays a crucial role in the pathogenesis of 
atherosclerosis.27,28 Accordingly, SR-A gene deficient mice bred with atherosclerosis-prone 
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apoE-/- or LDLrec-/- mice have been found to develop less atherosclerosis.29 We recently 
showed that ApoE-/- mice simultaneously lacking c-Jun N-terminal kinase 2 (ApoE-/- JNK2-/- 
mice) developed less atherosclerosis than do ApoE-/- mice.30 Macrophages lacking JNK-2 
displayed markedly decreased phosphorylation of SR-A and, hence, suppressed foam cell 
formation.30 Thus, upstream signaling molecules that regulate expression and function of SR-A 
may represent potential targets for therapeutic interventions.24 The present findings clearly 
indicates that SR-A expression in human MDMs is regulated by PKCβ. In contrast to SR-A, 
LOX-1 expression did not change after stimulation of MDMs with modified LDL. Furthermore, 
LY379196 did not exert any significant effect on LOX-1. Since SR-A expression was enhanced 
upon modified LDL stimulation and not LOX-1 we conclude that SR-A might be the primary 
receptor for modified LDL uptake. 
Several studies have strongly implicated activation of PKCβ in the pathogenesis of the vascular 
complications of diabetes.31 The synthesis of isoform-specific inhibitors for PKCβ has provided 
not only important insights into diabetic cardiovascular disease but also effective drugs against 
diabetic microvascular complications.15,32,33 Glucose-induced activation of PKCβ  may lead to 
endothelial dysfunction by causing activation of vascular NADPH oxidase, eNOS uncoupling 
and ROS production.6,34 Furthermore, high glucose enhances human macrophage LOX-1 
expression via PKCβ activation.20 Treatment with PKCβ inhibitor prevents impaired 
endothelium-dependent vasodilation caused by hyperglycemia.5 We demonstrated that selective 
inhibition of PKCβ2 inhibits glucose-induced VCAM-1 expression in human endothelial cells.7 
Interestingly enough, our data unmasks an antiatherosclerotic effect of PKCβ  inhibitors even in 
the nondiabetic condition of hypercholesterolemia. Specific siRNA-mediated knockdown of 
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PKCβ further supports our conclusion. Indeed, upon silencing of PKCβ the LDL uptake was 
blunted, SR-A expression reduced and, hence, foam cell formation prevented.  
The molecular link between PKCβ signaling pathway, SR-A upregulation and uptake of modified 
LDL might involve Thr-642 phosphorylation within catalytic domain of PKCβ1. Indeed, 
inhibition of PKCβ either by LY379196 or inhibitory peptide myr-ψPKC blunting PMA/acLDL-
induced Thr-642 phosphorylation abolished upregulation of SR-A as well as LDL uptake of 
human MDMs. In contrast, selective inhibitor of PKCβ2 CGP53353 did not affect any of these 
events. According to our results phosphorylation of PKCβ1 at Thr-642 represents a selective 
regulatory mechanism for SR-A upregulation and foam cell formation.  
Of particular interest is the fact that in our study LY379196, as a drug targeting macrophages, 
prevents only foam cell formation without affecting macrophage host-defense activity. Indeed, 
LY379196 blunted modified LDL uptake but did not affect the expression of CD68, a marker of 
macrophage activation.35 We also demonstrated that LY379196 did not inhibit LPS-induced 
CD14 degradation nor TNFα release in human MDMs. Moreover, PKCβ knockdown or 
inhibition did not affect superoxide anion production. These findings rules out any effect of 
PKCβ inhibition on macrophage functioning in innate immunity. In agreement with our results 
PKCβ-deficient mice have not been reported to present any impairment of macrophage activity.36 
Although these mice show a reduced peritoneal population of B-1 lymphocytes, the absolute 
number of splenic B cells is similar to the wild type animals. Furthermore, the thymuses of 
PKCβ-deficient mice were of normal size and cellularity and contained CD4+CD8+ double-
positive cells and CD4+ or CD8+ single-positive cells at normal ratios.36  
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Earlier studies of the role of vascular PKCβ activation in diabetes were primarily focused on 
microvascular dysfunction.37,38 Indeed, PKCβ inhibitors are currently being tested in clinical 
trials with microvascular endpoints.12-14 In conclusion, the results of our study suggest a role for 
PKCβ in atherogenesis even in the nondiabetic condition and anticipate the application of PKCβ 
inhibitors as putative antiatherosclerotic drugs. However, before deciding whether PKCβ 
inhibitors deserve to be tested in clinical trials of atherosclerosis, animal models will help evolve 
our current suggestive in vitro evidence concerning pro-atherosclerotic role of PKCβ signaling.  
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Figure Legend 
 
 
Figure 1.  Fluorescent confocal microscopy of human MDMs after incubation with DiI-acLDL 
(A). Red particles in the cytoplasm represent internalized DiI-acLDL. LY379196 
(5x10-6 mol/L) abolished modified LDL uptake (B). In human MDMs, green staining 
shows intracellular distribution of PKCβ1 (C) and PKCβ2 (D). Staining for nuclei in 
blue with DAPI. 
 
Figure 2. FACS analysis of human MDMs in the presence or in the absence of LY379196 after 
24 hours incubation with DiI-acLDL (A) and DiI-oxLDL (B). LY379196 (5x10-6 
mol/L) blunted modified LDL uptake, blue color. CGP53353 did not shown any 
significant effect (data not shown). LY379196 exerted a dose-dependent inhibition of 
acLDL and oxLDL uptake (A and B, respectively). Results are presented as 
mean±SEM; n=4 in each group. *p<0.05 vs PMA plus acLDL or oxLDL, 
respectively. 
 
Figure 3.  Expression of Scavenger Receptor-A (SR-A) in PMA-induced human MDMs as well  
as after incubation with acLDL in the presence and in the absence of LY379196 (10-6 
mol/L) or CGP53353 (10-6 mol/L). SR-A mRNA expression assessed by real-time 
PCR is normalized to L28 mRNA. Results are presented as mean±SEM; n=3 in each 
group. *p<0.05 vs control, **p<0.05 vs PMA alone, †p<0.05 vs PMA plus acLDL.             
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Figure 4. Representative Western blot and densitometric quantification of SR-A protein 
expression in PMA-induced human MDMs as well as after incubation with acLDL 
(A) and oxLDL (B) in the presence and in the absence of LY379196 (10-6 mol/L) or 
CGP53353 (10-6 mol/L).  Inhibitory effect of myristoylated cell-permeable peptide, 
myr-ψPKC on SR-A protein expression in PMA-induced human MDMs after 
incubation with acLDL (C). Lectin-like Oxidized low density lipoprotein receptor 1 
(LOX-1) protein expression in PMA-induced human MDMs as well as after 
incubation with acLDL and oxLDL in the presence and in the absence of LY379196 
(D).  Results are presented as mean±SEM; n=4 in each group. *p<0.05 vs control, 
**p<0.05 vs PMA alone, †p<0.05 vs PMA plus acLDL or oxLDL, respectively. 
 
Figure 5. Representative Western blot and densitometric quantification of PKCβ (Α) and SR-A 
(C) protein expression after transfection of selective PKCβ siRNA into MDMs. FACS 
analysis of transfected human MDMs after 24 hours incubation with DiI-acLDL (B). 
Upon silencing of PKCβ the uptake of modified LDL and SR-A expression are 
reduced . GAPDH and Mock served as controls. Results are presented as mean±SEM; 
n=4 in each group. *p<0.05 vs Mock and GAPDH, respectively. 
 
Figure 6. Representative Western blot and densitometric quantification of PKCβ1 
phosphorylation at the Thr-642 residue in PMA-induced human MDMs after 
incubation with acLDL in the presence and in the absence of LY379196 (10-6 mol/L), 
CGP53353 (10-6 mol/L) or myr-ψPKC (10-4 mol/L). Results are presented as 
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mean±SEM; n=4 in each group. *p<0.05 vs control, **p<0.05 vs PMA alone, †p<0.05 
vs PMA plus acLDL. 
 
Figure 7.  Treatment with LY379196 (10-6 mol/L) affects SR-A expression but not activation of 
human MDMs stimulated with acLDL. SR-A (A and B) and CD68, a marker of 
macrophage activation, (C and D) are shown by fluorescent confocal microscopy. The 
nuclei stained with DAPI are blue in colour, whereas SR-A and CD68 stainings are 
both green.  
 
Figure 8. LY379196 did not inhibit LPS-induced CD14 degradation, TNFα release nor 
superoxide anion (O2-) production in human MDMs. Representative Western blot and 
densitometric quantification of  CD14 expression (A), TNFα levels in supernatant (B) 
after 24 hours stimulation with LPS (100ng/mL). O2- production after incubation with 
acLDL and oxLDL (10 µg/mL, C). Results are presented as mean±SEM; n=3-5 in 
each group.                                                         
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